ASND vs IVA
Ascendis Pharma A/S and Inventiva S.a., side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | IVA |
|---|---|---|
| Revenue | €720.1M | €9.2M |
| Net income | €-228.0M | €-184.2M |
| Gross margin | 86.8% | · |
| Net margin | −31.7% | · |
| Return on equity | · | · |
| Diluted EPS | −€3.76 | −€3.08 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | · |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 1.04× | 0.92× |
| Revenue CAGR 5y | 153.0% | 5.6% |
| Profit CAGR 5y | · | · |
ASND bills 78.3× the revenue of IVA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | ASND | IVA |
|---|---|---|
| FY2024 | €363.6M | €9.2M |
| FY2023 | €266.7M | €17.5M |
| FY2022 | €51.2M | €12.2M |
| FY2021 | €7.8M | €4.2M |
| FY2020 | €7.0M | €372,000 |
| FY2019 | €13.4M | €7.0M |
| FY2018 | €10.6M | €3.2M |
Bottom line
| Fiscal year | ASND | IVA |
|---|---|---|
| FY2024 | €-378.1M | €-184.2M |
| FY2023 | €-481.4M | €-110.4M |
| FY2022 | €-583.2M | €-54.3M |
| FY2021 | €-383.6M | €-49.6M |
| FY2020 | €-419.0M | €-33.6M |
| FY2019 | €-218.0M | €-30.2M |
| FY2018 | €-130.1M | €-33.0M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +€354,443,000 | ASND |
| FY2023 | +€249,241,000 | ASND |
| FY2022 | +€38,995,000 | ASND |
| FY2021 | +€3,584,000 | ASND |
| FY2020 | +€6,581,000 | ASND |
| FY2019 | +€6,377,000 | ASND |
| FY2018 | +€7,384,000 | ASND |
ASND has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than IVA's over the 3 comparable fiscal years — 474.7 percentage points of standard deviation against 244.9.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ASND and IVA over these 3 fiscal years — ASND led in 1 and IVA in 2.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than IVA's over the 5 comparable fiscal years — 20.4 percentage points of standard deviation against 12.7.
5 of 8 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ASND and IVA over these 5 fiscal years — ASND led in 2 and IVA in 3.
5 of 8 comparable fiscal years — a year missing data on either side is not counted.